D441 OBJECTIVE ASSESSMENT – WGU PHARMACOLOGY OA – (2026)
ACTUAL QUESTIONS & STUDY GUIDE | GUARANTEE PASS
WGU D441 PHARMACOLOGY OBJECTIVE ASSESSMENT EXAM & STUDY GUIDE
COURSE: D441 – PHARMACOLOGY
TARGET: OBJECTIVE ASSESSMENT (OA) PRACTICE EXAM & STUDY GUIDE
FORMAT: MULTIPLE-CHOICE (A–D) WITH CORRECT ANSWER KEY AND TARGETED CLINICAL
RATIONALES
DIFFICULTY BREAKDOWN: 30% BASIC RECALL, 50% APPLICATION (CLINICAL SCENARIOS), 20%
ANALYSIS & CRITICAL THINKING
Table of Contents
Section Domain / Subject Focus Question Range
Section 1 General Principles: Pharmacokinetics & Pharmacodynamics Questions 1–50
Section 2 Cardiovascular, Renal, & Hematologic Agents Questions 51–100
Section 3 Neurological, Autonomic, & Psychotropic Pharmacology Questions 101–150
Section 4 Endocrine, Antimicrobial, & Systemic Therapies Questions 151–200
Section 1: General Principles – Pharmacokinetics & Pharmacodynamics
Question 1
Difficulty: Basic Recall
A patient with chronic renal failure is prescribed a drug primarily excreted by the kidneys. How
will the patient's impaired renal function affect the drug’s pharmacokinetics?
A. Increase the clearance rate of the drug
B. Prolong the elimination half-life (𝑡1/2 ) of the drug
C. Decrease the total bioavailability of oral formulations
D. Accelerate hepatic first-pass metabolism
• Correct Answer: B
, • Rationale: Impaired renal clearance reduces the excretion rate of drugs eliminated via
glomerular filtration or tubular secretion, directly prolonging the drug's elimination half-
life (𝑡1/2 ). Distractor A is incorrect because clearance decreases rather than increases in
renal impairment.
Question 2
Difficulty: Application
A nurse administers an intravenous bolus of Medication X, an agonist with high intrinsic activity,
followed by a continuous infusion. Later, a competitive antagonist targeting the same receptor is
introduced. What effect will increasing the concentration of Medication X have on the
therapeutic response in the presence of this competitive antagonist?
A. The maximum efficacy (𝐸max ) will be permanently lowered regardless of Medication X
concentration.
B. The agonist curve will shift to the right, requiring a higher dose of Medication X to achieve
the maximal response.
C. Medication X will act as an inverse agonist, producing an opposite pharmacological effect.
D. The competitive antagonist will form an irreversible covalent bond, blocking Medication X
entirely.
• Correct Answer: B
• Rationale: Competitive antagonists reversibly bind to the active receptor site, which
shifts the concentration-response curve to the right without lowering maximal efficacy
(𝐸max ); overcoming the blockade requires higher concentrations of the agonist. Distractor
A describes a noncompetitive antagonist, which reduces maximal efficacy regardless of
agonist concentration.
Question 3
Difficulty: Analysis/Critical Thinking
A 68-year-old female patient with severe hypoalbuminemia (serum albumin 2.1 g/dL) is
prescribed phenytoin, a highly protein-bound drug (90%). Which pharmacokinetic alteration
should the clinician anticipate when interpreting the patient's drug levels and clinical status?
A. The total serum concentration of phenytoin will appear elevated, increasing total toxicity.
B. The free, unbound fraction of phenytoin will increase, elevating the risk of toxicity despite
normal or low total drug levels.
,C. The volume of distribution (𝑉𝑑 ) will decrease significantly, keeping the drug confined to the
intravascular compartment.
D. Hepatic clearance will cease entirely due to lack of protein-mediated transport.
• Correct Answer: B
• Rationale: Phenytoin extensively binds to serum albumin; hypoalbuminemia decreases
available binding sites, increasing the biologically active free (unbound) fraction of the
drug and increasing risk of toxicity even if total drug levels test within normal reference
ranges. Distractor C is incorrect because a lower bound fraction increases 𝑉𝑑 as more
unbound drug distributes into peripheral tissues.
Section 2: Cardiovascular, Renal, & Hematologic Agents
Question 4
Difficulty: Application
A 55-year-old male with heart failure with reduced ejection fraction (HFrEF) is started on
lisinopril. Two weeks later, laboratory testing reveals a serum potassium level of 5.8 mEq/L and
a serum creatinine increase from 1.0 mg/dL to 1.2 mg/dL. What is the primary mechanism
responsible for the elevation in serum potassium?
A. Inhibition of sodium-potassium ATPase pumps in the loop of Henle
B. Blockade of angiotensin II-mediated aldosterone secretion in the adrenal cortex
C. Direct activation of mineralocorticoid receptors in the collecting duct
D. Suppression of renal erythropoietin production in the juxtaglomerular apparatus
• Correct Answer: B
• Rationale: ACE inhibitors like lisinopril block the conversion of angiotensin I to
angiotensin II, decreasing aldosterone secretion; reduced aldosterone decreases renal
distal tubule potassium excretion, leading to hyperkalemia. Distractor A is incorrect
because ACE inhibitors do not act on loop Na+/K+-ATPase pumps.
Question 5
Difficulty: Basic Recall
Which class of antihypertensive medications is strictly contraindicated during pregnancy due to
the risk of fetal renal dysgenesis and oligohydramnios?
A. Calcium channel blockers (e.g., nifedipine)
B. Beta-adrenergic blockers (e.g., labetalol)
, C. Angiotensin receptor blockers (ARBs)
D. Central alpha-2 agonists (e.g., methyldopa)
• Correct Answer: C
• Rationale: Angiotensin receptor blockers (ARBs) and ACE inhibitors are teratogenic
(FDA category D/X equivalency) and cause fetal renal failure, oligohydramnios, and
cranial hypoplasia. Distractor B and D (labetalol and methyldopa) are widely used as safe
first-line options in pregnancy-induced hypertension.
Section 3: Neurological, Autonomic, & Psychotropic Pharmacology
Question 6
Difficulty: Application
A patient with major depressive disorder is prescribed phenelzine, a monoamine oxidase
inhibitor (MAOI). During a dietary assessment, the nurse instructs the patient to avoid aged
cheeses, cured meats, and draft beers. What acute complication is prevented by following these
dietary restrictions?
A. Serotonin syndrome characterized by hyperreflexia and clonus
B. Severe hypertensive crisis resulting from un-metabolized exogenous tyramine
C. Neuroleptic malignant syndrome with rigidity and hyperthermia
D. Acute agranulocytosis caused by bone marrow suppression
• Correct Answer: B
• Rationale: MAOIs inhibit gastrointestinal and hepatic MAO-A, preventing the
degradation of dietary tyramine; systemic accumulation of tyramine causes massive
norepinephrine displacement and acute hypertensive crisis. Distractor A is incorrect
because tyramine ingestion specifically drives catecholamine release/hypertensive crisis
rather than serotonin syndrome (which results from combining MAOIs with serotonergic
agents like SSRIs).
Question 7
Difficulty: Analysis/Critical Thinking
A patient presenting with acute organophosphate insecticide poisoning exhibits severe
bradycardia, bronchorrhea, bronchospasm, diaphoresis, and excessive lacrimation. Which
medication should be administered immediately to reverse these muscarinic symptoms?
A. Pralidoxime (2-PAM)
ACTUAL QUESTIONS & STUDY GUIDE | GUARANTEE PASS
WGU D441 PHARMACOLOGY OBJECTIVE ASSESSMENT EXAM & STUDY GUIDE
COURSE: D441 – PHARMACOLOGY
TARGET: OBJECTIVE ASSESSMENT (OA) PRACTICE EXAM & STUDY GUIDE
FORMAT: MULTIPLE-CHOICE (A–D) WITH CORRECT ANSWER KEY AND TARGETED CLINICAL
RATIONALES
DIFFICULTY BREAKDOWN: 30% BASIC RECALL, 50% APPLICATION (CLINICAL SCENARIOS), 20%
ANALYSIS & CRITICAL THINKING
Table of Contents
Section Domain / Subject Focus Question Range
Section 1 General Principles: Pharmacokinetics & Pharmacodynamics Questions 1–50
Section 2 Cardiovascular, Renal, & Hematologic Agents Questions 51–100
Section 3 Neurological, Autonomic, & Psychotropic Pharmacology Questions 101–150
Section 4 Endocrine, Antimicrobial, & Systemic Therapies Questions 151–200
Section 1: General Principles – Pharmacokinetics & Pharmacodynamics
Question 1
Difficulty: Basic Recall
A patient with chronic renal failure is prescribed a drug primarily excreted by the kidneys. How
will the patient's impaired renal function affect the drug’s pharmacokinetics?
A. Increase the clearance rate of the drug
B. Prolong the elimination half-life (𝑡1/2 ) of the drug
C. Decrease the total bioavailability of oral formulations
D. Accelerate hepatic first-pass metabolism
• Correct Answer: B
, • Rationale: Impaired renal clearance reduces the excretion rate of drugs eliminated via
glomerular filtration or tubular secretion, directly prolonging the drug's elimination half-
life (𝑡1/2 ). Distractor A is incorrect because clearance decreases rather than increases in
renal impairment.
Question 2
Difficulty: Application
A nurse administers an intravenous bolus of Medication X, an agonist with high intrinsic activity,
followed by a continuous infusion. Later, a competitive antagonist targeting the same receptor is
introduced. What effect will increasing the concentration of Medication X have on the
therapeutic response in the presence of this competitive antagonist?
A. The maximum efficacy (𝐸max ) will be permanently lowered regardless of Medication X
concentration.
B. The agonist curve will shift to the right, requiring a higher dose of Medication X to achieve
the maximal response.
C. Medication X will act as an inverse agonist, producing an opposite pharmacological effect.
D. The competitive antagonist will form an irreversible covalent bond, blocking Medication X
entirely.
• Correct Answer: B
• Rationale: Competitive antagonists reversibly bind to the active receptor site, which
shifts the concentration-response curve to the right without lowering maximal efficacy
(𝐸max ); overcoming the blockade requires higher concentrations of the agonist. Distractor
A describes a noncompetitive antagonist, which reduces maximal efficacy regardless of
agonist concentration.
Question 3
Difficulty: Analysis/Critical Thinking
A 68-year-old female patient with severe hypoalbuminemia (serum albumin 2.1 g/dL) is
prescribed phenytoin, a highly protein-bound drug (90%). Which pharmacokinetic alteration
should the clinician anticipate when interpreting the patient's drug levels and clinical status?
A. The total serum concentration of phenytoin will appear elevated, increasing total toxicity.
B. The free, unbound fraction of phenytoin will increase, elevating the risk of toxicity despite
normal or low total drug levels.
,C. The volume of distribution (𝑉𝑑 ) will decrease significantly, keeping the drug confined to the
intravascular compartment.
D. Hepatic clearance will cease entirely due to lack of protein-mediated transport.
• Correct Answer: B
• Rationale: Phenytoin extensively binds to serum albumin; hypoalbuminemia decreases
available binding sites, increasing the biologically active free (unbound) fraction of the
drug and increasing risk of toxicity even if total drug levels test within normal reference
ranges. Distractor C is incorrect because a lower bound fraction increases 𝑉𝑑 as more
unbound drug distributes into peripheral tissues.
Section 2: Cardiovascular, Renal, & Hematologic Agents
Question 4
Difficulty: Application
A 55-year-old male with heart failure with reduced ejection fraction (HFrEF) is started on
lisinopril. Two weeks later, laboratory testing reveals a serum potassium level of 5.8 mEq/L and
a serum creatinine increase from 1.0 mg/dL to 1.2 mg/dL. What is the primary mechanism
responsible for the elevation in serum potassium?
A. Inhibition of sodium-potassium ATPase pumps in the loop of Henle
B. Blockade of angiotensin II-mediated aldosterone secretion in the adrenal cortex
C. Direct activation of mineralocorticoid receptors in the collecting duct
D. Suppression of renal erythropoietin production in the juxtaglomerular apparatus
• Correct Answer: B
• Rationale: ACE inhibitors like lisinopril block the conversion of angiotensin I to
angiotensin II, decreasing aldosterone secretion; reduced aldosterone decreases renal
distal tubule potassium excretion, leading to hyperkalemia. Distractor A is incorrect
because ACE inhibitors do not act on loop Na+/K+-ATPase pumps.
Question 5
Difficulty: Basic Recall
Which class of antihypertensive medications is strictly contraindicated during pregnancy due to
the risk of fetal renal dysgenesis and oligohydramnios?
A. Calcium channel blockers (e.g., nifedipine)
B. Beta-adrenergic blockers (e.g., labetalol)
, C. Angiotensin receptor blockers (ARBs)
D. Central alpha-2 agonists (e.g., methyldopa)
• Correct Answer: C
• Rationale: Angiotensin receptor blockers (ARBs) and ACE inhibitors are teratogenic
(FDA category D/X equivalency) and cause fetal renal failure, oligohydramnios, and
cranial hypoplasia. Distractor B and D (labetalol and methyldopa) are widely used as safe
first-line options in pregnancy-induced hypertension.
Section 3: Neurological, Autonomic, & Psychotropic Pharmacology
Question 6
Difficulty: Application
A patient with major depressive disorder is prescribed phenelzine, a monoamine oxidase
inhibitor (MAOI). During a dietary assessment, the nurse instructs the patient to avoid aged
cheeses, cured meats, and draft beers. What acute complication is prevented by following these
dietary restrictions?
A. Serotonin syndrome characterized by hyperreflexia and clonus
B. Severe hypertensive crisis resulting from un-metabolized exogenous tyramine
C. Neuroleptic malignant syndrome with rigidity and hyperthermia
D. Acute agranulocytosis caused by bone marrow suppression
• Correct Answer: B
• Rationale: MAOIs inhibit gastrointestinal and hepatic MAO-A, preventing the
degradation of dietary tyramine; systemic accumulation of tyramine causes massive
norepinephrine displacement and acute hypertensive crisis. Distractor A is incorrect
because tyramine ingestion specifically drives catecholamine release/hypertensive crisis
rather than serotonin syndrome (which results from combining MAOIs with serotonergic
agents like SSRIs).
Question 7
Difficulty: Analysis/Critical Thinking
A patient presenting with acute organophosphate insecticide poisoning exhibits severe
bradycardia, bronchorrhea, bronchospasm, diaphoresis, and excessive lacrimation. Which
medication should be administered immediately to reverse these muscarinic symptoms?
A. Pralidoxime (2-PAM)
